Evgen Pharma (GB:TCF) has released an update.
TheraCryf, the clinical-stage drug development company, announced positive results from a pharmacokinetic study on its SFX-01 tablet, which demonstrated effective delivery and safety in healthy volunteers. The study’s publication in Advances in Therapy marks a significant milestone in TheraCryf’s plans for future studies, particularly in treating glioblastoma. Investors may find interest as the company aims to partner its programs with larger pharmaceutical companies for commercialization.
For further insights into GB:TCF stock, check out TipRanks’ Stock Analysis page.
